Neuromyelitis optica (Devic's syndrome)

Handbook of Clinical Neurology

Volumn 122, Issue , 2014, Pages 581-599

  Wingerchuk, Dean M ^a   Weinshenker, Brian G ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Aquaporin 4; Astrocyte; Clinical features; Neuromyelitis optica; Optic neuritis; Transverse myelitis

Indexed keywords

AQUAPORIN 4; AUTOANTIBODY;

AQUAPORIN-4; ARTICLE; ASTROCYTE; BLOOD; CEREBROSPINAL FLUID; CLINICAL FEATURE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; PROGNOSIS; RECURRENT DISEASE;

AQUAPORIN-4; ASTROCYTE; CLINICAL FEATURES; NEUROMYELITIS OPTICA; OPTIC NEURITIS; TRANSVERSE MYELITIS;

AQUAPORIN 4; AUTOANTIBODIES; HUMANS; NEUROMYELITIS OPTICA; PROGNOSIS; RECURRENCE;

EID: 84893447772     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52001-2.00025-X     Document Type: Chapter

References (138)

1. Achard C., Guinon L. Sur un cas de myelite aigue diffuse avec double nevrite optique. Arch Med Exp Anat Pathol 1889, 1:696-710.
2. Al-Araji A.H., Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler 2005, 11:398-402.
3. Albutt T.C. On the ophthalmoscopic signs of spinal disease. Lancet 1870, 1:76-78.
4. Amiry-Moghaddam M., Ottersen O.P. The molecular basis of water transport in the brain. Nat Rev Neurosci 2003, 4:991-1001.
5. Asgari N., Lillevang S.T., Skejoe H.P., et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011, 76:1589-1595.
6. Bakker J., Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004, 31:265-267.
7. Barkhof F., Filippi M., Miller D.H., et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997, 120:2059-2069.
8. Beck G.M. A case of diffuse myelitis associated with optic neuritis. Brain 1927, 50:687-703.
9. Bergamaschi R. Glatiramer acetate treatment in Devic's neuromyelitis optica. Brain 2003, 126. 1E; author reply 1E-a.
10. Bichuetti D.B., Lobato Oliveira E.M., de Castro Boulos F., et al. Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Arch Neurol 2012, 69:938-939.
11. Bizzoco E., Lolli F., Repice A.M., et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 2009, 256:1891-1898.
12. Bonnan N., Valentino R., Olindo S., et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009, 15:487-492.
13. Bot J.C., Barkhof F., Polman C.H., et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004, 62:226-233.
14. Bradl M., Misu T., Takahashi T., et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009, 66:630-643.
15. Brück W., Popescu B., Lucchinetti C.F., et al. Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann Neurol 2012, 72:385-394.
16. Brum D.G., Barreira A.A., dos Santos A.C., et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler 2010, 16:21-29.
17. Cabre P., Heinzlef O., Merle H., et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001, 56:507-514.
18. Cabrera-Gomez J.A., Kurtzke J.F., Gonzalez-Quevedo A., et al. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009, 256:34-44.
19. Ch'ien L.T., Medeiros M.O., Belluomini J.J., et al. Neuromyelitis optica (Devic's syndrome) in two sisters. Clin Electroencephalogr 1982, 13:36-39.
20. Chihara N., Aranami T., Sato W., et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011, 108:3701-3706.
21. Neuromyelitis Optica 1970, vol. 9. North-Holland, Amsterdam. D.E. Cloys, M.G. Netsky (Eds.).
22. Compston A. The marvellous harmony of the nervous parts: The origins of multiple sclerosis. Clin Med 2004, 4:346-354.
23. Costanzi C., Matiello M., Lucchinetti C.F., et al. Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011, 77:659-666.
24. Cree B.A., Goodin D.S., Hauser S.L. Neuromyelitis optica. Semin Neurol 2002, 22:105-122.
25. Cree B.A., Lamb S., Morgan K., et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270-1272.
26. Das A., Puvanendran K. A retrospective review of patients with clinically definite multiple sclerosis. Ann Acad Med Singapore 1998, 27:204-209.
27. de Seze J. Neuromyelitis optica. Arch Neurol 2003, 60:1336-1338.
28. de Seze J., Lebrun C., Stojkovic T., et al. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003, 9:521-525.
29. Devic E. Myelite aigue compliquee de nevrite optique, autopsie. Bull Med (Paris) 1894, 8.
30. Ebers G.C., Paty D.W. CSF electrophoresis in one thousand patients. Can J Neurol Sci 1980, 7:275-280.
31. Erb W. Uber das Zusammenkommen von Neuritis optika und Myelitis subacuta. Arch Psychiatr Nervenkr 1880, 1:146-157.
32. Fardet L., Genereau T., Mikaeloff Y., et al. Devic's neuromyelitis optica: study of nine cases. Acta Neurol Scand 2003, 108:193-200.
33. Ferraro A. Primary demyelinating processes of the central nervous system: an attempt at unification and classification. Arch Neurol Psychiat (Chic) 1937, 37:1100-1160.
34. Ford B., Tampieri D., Francis G. Long-term follow-up of acute partial transverse myelopathy. Neurology 1992, 42:250-252.
35. Fukazawa T., Kikuchi S., Sasaki H., et al. Genomic HLA profiles of MS in Hokkaido, Japan: important role of DPB1*0501 allele. J Neurol 2000, 247:175-178.
36. Gangopadhyay G., Das S., Sarda P., et al. Clinical profile of multiple sclerosis in Bengal. Neurol India 1999, 47:18-21.
37. Gault F. De la neuromyelite optique aigue 1894, Lyon.
38. Ghezzi A., Bergamaschi R., Martinelli V., et al. Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica. J Neurol 2004, 251:47-52.
39. Gold R., Linington C. Devic's disease: bridging the gap between laboratory and clinic. Brain 2002, 125:1425-1427.
40. Goulden C. Optic neuritis and myelitis. Ophthal Rev 1914, 34:193-209.
41. Hassin G.B. Neuroptic myelitis versus multiple sclerosis: a pathologic study. Arch Neurol Psychiat (Chic) 1937, 37:1083-1099.
42. Jacob A., Weinshenker B.G., Violich I., et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008, 65:1443-1448.
43. Jacob A., Matiello M., Weinshenker B.G., et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009, 66:1128-1133.
44. Jarius S., Wildemann B. An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS. Mult Scler 2011, 17:1384-1386.
45. Jarius S., Wildemann B. 'Noteomielite' accompanied by acute amaurosis (1844). On an early case of neuromyelitis optica. J Neurol Sci 2012, 313:182-184.
46. Jarius S., Wildemann B. The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation. J Neurol 2012, 259:1354-1357.
47. Kanamori Y., Nakashima I., Takai Y., et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology 2011, 77:652-658.
48. Keegan M., Pineda A.A., McClelland R.L., et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002, 58:143-146.
49. Kim W., Su Park Min, Hyun Lee Sang, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 2010, 16:1229-1236.
50. Kim S.H., Kim W., Park M.S., et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011, 68:473-479.
51. Kimbrough D., Fujihara K., Jacob A., et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 2012, 1:180-187.
52. Kinoshita M., Nakatsuji Y., Kimura T., et al. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun 2010, 394:205-210.
53. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003, 2:117-127.
54. Kira J., Yamasaki K., Horiuchi I., et al. Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan. J Neurol Sci 1999, 166:53-57.
55. Kitley J., Leite M.I., Nakashima I., et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012, 135:1834-1849.
56. Kitley J., Elsone L., George J., et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 2013, 84:918-921.
57. Kleiter I., Hellwig K., Berthele A., et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012, 69:239-245. Neuromyelitis Optica Study Group.
58. Kohut H., Richter R.B. Neuro-optic myelitis: a clinicopathological study of two related cases. J Nerv Ment Dis 1945, 101:99-114.
59. Lau K., Wong L., Li L., et al. Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey. Hong Kong Med J 2002, 8:77-80.
60. Lee D.H., Metz I., Berthele A., et al. Supraspinal demyelinating lesions in neuromyelitis optica display a typical astrocyte pathology. Neuropathol Appl Neurobiol 2010, 36:685-687.
61. Lennon V.A., Wingerchuk D.M., Kryzer T.J., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
62. Lennon V.A., Kryzer T.J., Pittock S.J., et al. IgG marker of optic-spinal MS binds to the aquaporin 4 water channel. J Exp Med 2005, 202:473-477.
63. Lucchinetti C.F., Mandler R.N., McGavern D., et al. Brain 2002, 125:1450-1461.
64. Magana S.M., Matiello M., Pittock S.J., et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009, 72:712-717.
65. Mandler R.N., Davis L.E., Jeffery D.R., et al. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993, 34:162-168.
66. Mandler R.N., Ahmed W., Dencoff J.E. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219-1220.
67. Mani J., Chaudhary N., Ravat S., et al. Multiple sclerosis:experience in neuroimaging era from western India. Neurol India 1999, 47:8-11.
68. Matiello M., Schaefer-Klein J., Brum D.G., et al. HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica. Mult Scler 2010, 16:981-984.
69. Matiello M., Kim H.J., Kim W. Familial neuromyelitis optica. Neurology 2010, 75:310-315.
70. Matiello M., Schaefer-Klein J., Sun D., et al. Aquaporin-4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol 2013, 70:1118-1125.
71. Matthews L., Marasco R., Jenkinson M., et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 2013, 80:1-8.
72. McAlpine D. Familial neuromyelitis optica: Its occurrence in identical twins. Brain 1938, 61:430-448.
73. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
74. McLean B.N., Luxton R.W., Thompson E.J. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index A comparison and diagnostic applications. Brain 1990, 113:1269-1289.
75. Miller H.G., Evans M.J. Prognosis in acute disseminated encephalomyelitis: with a note on neuromyelitis optica. Q J Med 1953, 22:347-379.
76. Min J.H., Kim B.J., Lee K.H., et al. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012, 18:113-115.
77. Mirsattari S.M., Johnston J.B., McKenna R., et al. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology 2001, 56:317-323.
78. Misu T., Fujihara K., Nakashima I., et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002, 125:2460-2468.
79. Misu T., Fujihara K., Nakashima I., et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005, 65:1479-1482.
80. Misu T., Kakita A., Fujihara K., et al. A comparative neuropathological analysis of Japanese cases of neuromyelitis optica and multiple sclerosis. Neurology 2005, 64:A39.
81. Modi G., Mochan A., Modi M., et al. Demyelinating disorder of the central nervous system occurring in black South Africans. J Neurol Neurosurg Psychiatry 2001, 70:500-505.
82. Nakamura M., Miyazawa I., Fujihara K., et al. Preferential spinal central gray matter involvement in neuromyelitis optica An MRI study. J Neurol 2008, 255:163-170.
83. Nakashima I., Fujihara K., Takase S., et al. Decrease in multiple sclerosis with acute transverse myelitis in Japan. Tohoku J Exp Med 1999, 188:89-94.
84. Nakashima I., Fujihara K., Fujimori J., et al. Absence of IgG1 response in the cerebrospinal fluid of relapsing neuromyelitis optica. Neurology 2004, 62:144-146.
85. Nielsen J.M., Korteweg T., Barkhof F., et al. Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. Ann Neurol 2005, 58:781-783.
86. O'Riordan J.I., Gallagher H.L., Thompson A.J., et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996, 60:382-387.
87. Osuntokun B.O. The pattern of neurological illness in tropical Africa Experience at Ibadan, Nigeria. J Neurol Sci 1971, 12:417-442.
88. Papais-Alvarenga R.M., Miranda-Santos C.M., Puccioni-Sohler M., et al. Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neurosurg Psychiatry 2002, 73:429-435.
89. Papeix C., Vidal J.S., de Seze J., et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007, 13:256-259.
90. Paty D.W., Oger J.J., Kastrukoff L.F., et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988, 38:180-185.
91. Pirko I., Blauwet L.K., Lesnick T.G., et al. The natural history of recurrent optic neuritis. Arch Neurol 2004, 61:1401-1405.
92. Pittock S.J., Weinshenker B.G., Wijdicks E.F. Mechanical ventilation and tracheostomy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2004, 75:1331-1333.
93. Pittock S.J., Lennon V.A., de Seze J., et al. Neuromyelitis optica and non-organ-specific autoimmunity. Arch Neurol 2005, 65:78-83.
94. Pittock S.J., Lennon V.A., Krecke K., et al. Brain MRI abnormalities in neuromyelitis optica. Arch Neurol 2006, 63:390-396.
95. Pittock S.J., Weinshenker B.G., Lucchinetti C.F., et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin-4 expression. Arch Neurol 2006, 63:964-968.
96. Pittock S.J., Lennon V.A., McKeon A., et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013, 2013 Apr 25.
97. Poppe A.Y., Lapierre Y., Melancon D., et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005, 11:617-621.
98. Demyelinating Diseases 1997, Arnold, London. J.W. Prineas, W.I. McDonald (Eds.).
99. Putnam T.J., Forster F.M. Neuromyelitis optica; its relation to multiple sclerosis. Trans Am Neurol Assoc 1942, 68:20-25.
100. Quek A.M.L., McKeon A., Lennon V.A., et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol 2012, 69:1039-1043.
101. Ropper A.H., Miett T., Chiappa K.H. Absence of evoked potential abnormalities in acute transverse myelopathy. Neurology 1982, 32:80-82.
102. Ruprecht K., Klinker E., Dintelmann T., et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004, 63:1081-1083.
103. Saadoun S., Waters P., Bell B.A., et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2009, 133:349-361.
104. Saida T., Tashiro K., Itoyama Y., et al. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005, 64:621-630.
105. Scolding N. Devic's disease and autoantibodies. Lancet Neurol 2005, 4:136-137.
106. Scott T.F., Bhagavatula K., Snyder P.J., et al. Transverse myelitis Comparison with spinal cord presentations of multiple sclerosis. Neurology 1998, 50:429-433.
107. Shimizu J., Hatanaka Y., Hasagawa M., et al. IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010, 75:1423-1427.
108. Silber M.H., Willcox P.A., Bowen R.M., et al. Neuromyelitis optica (Devic's syndrome) and pulmonary tuberculosis. Neurology 1990, 40:934-938.
109. Stansbury F.C. Neuromyelitis optica; presentation of five cases, with pathologic study, and review of literature. Arch Ophthal 1949, 42:465-501.
110. Storch M.K., Stefferl A., Brehm U., et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998, 8:681-694.
111. Syal P., Prabhakar S., Thussu A., et al. Clinical profile of multiple sclerosis in north-west India. Neurol India 1999, 47:12-17.
112. Takano R., Misu T., Takahashi T., et al. Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study. Neurology 2010, 20(75):208-216.
113. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
114. Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology 2000, 20(Suppl):S20-S24.
115. Thielen K.R., Miller G.M. Multiple sclerosis of the spinal cord: magnetic resonance appearance. J Comput Assist Tomogr 1996, 20:434-438.
116. Tintore M., Rovira A., Martinez M.J., et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000, 21:702-706.
117. Tradtrantip L., Zhang H., Saadoun S., et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012, 71:314-322.
118. Tradtrantip L., Zhang H., Anderson M.O., et al. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J 2012, 6:2197-2208.
119. Tradtrantip L., Ratelade J., Zhang H., et al. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 2013, 73:77-85.
120. Vernant J.C., Cabre P., Smadja D., et al. Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology 1997, 48:58-64.
121. Watanabe S., Nakashima I., Misu T., et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007, 13:128-132.
122. Waters P.J., McKeon A., Leite M.I., et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012, 78:665-671.
123. Weinshenker B.G. Neuromyelitis optica: what it is and what it might be. Lancet 2003, 361:889-890.
124. Weinshenker B.G. Western vs optic-spinal MS: two diseases, one treatment?. Neurology 2005, 64:594-595.
125. Weinshenker B.G., O'Brien P.C., Petterson T.M., et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878-886.
126. Weinshenker B.G., Wingerchuk D.M., Vukusic S., et al. NMO-IgG predicts relapse following longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566-569.
127. Wingerchuk D.M. Neuromyelitis optica: current concepts. Front Biosci 2004, 9:834-840.
128. Wingerchuk D.M., Weinshenker B.G. Neuromyelitis optica 2003, Butterworth-Heinemann, Woburn, MA.
129. Wingerchuk D.M., Weinshenker B.G. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003, 60:848-853.
130. Wingerchuk D.M., Weinshenker B.G. Neuromyelitis Optica. Curr Treat Options Neurol 2008, 10:55-66.
131. Wingerchuk D.M., Weinshenker B.G. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 2012, 18:5-10.
132. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
133. Wingerchuk D.M., Lennon V.A., Pittock S.J., et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
134. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
135. Wingerchuk D.M., Pittock S.J., Lucchinetti C.F., et al. A secondary progressive course is uncommon in neuromyelitis optica. Neurology 2007, 68:603-605.
136. Yamasaki K., Horiuchi I., Minohara M., et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain 1999, 122:1689-1696.
137. Zaffaroni M. Cerebrospinal fluid findings in Devic's neuromyelitis optica. Neurol Sci 2004, 25:S368-S370. Italian Devic's Study Group.
138. Zephir H., Fajardy I., Outteryck O., et al. Is neuromyelitis optica associated with human leukocyte antigen?. Mult Scler 2009, 15:571-579.